The article has two parts. The first part talks about labs that are creating an elaborate digital ecosystem around the traditional molecular lab services - "Lab 3.0." The second part talks about companies that are being established without any wetlab, and dedicated to providing digital genomic services like state of the art outsourced software, analytics, and bioinformatics pipelines.

click to enlarge

This continues to be an active area of investment, e.g. a $58M investment in DNANexus was announced on January 2, here.

About the Author

Bruce Quinn MD PhD is an expert on health reform, innovation, and Medicare policy. He helps both large and small companies understand and overcome hurdles to commercialization, as well as craft business strategies for a changing environment. CONTACT Dr. Quinn through www.brucequinn.com. BACKGROUND: Dr. Quinn has worked in academic medicine, Accenture business strategies, and for the Medicare program. EDUCATION: Stanford MD/PhD, MIT Postdoc, Kellogg MBA.